<DOC>
	<DOCNO>NCT01175395</DOCNO>
	<brief_summary>The primary purpose study ass safety &amp; tolerability investigational drug 20089 TA ( 6.9 mg 13.8 mg ) use adjunctively Lucentis 0.5 mg subject sub-foveal neovascular AMD .</brief_summary>
	<brief_title>20089 TA+Lucentis Combo Intravitreal Injections Treatment Neovascular Age-related Macular Degeneration ( AMD )</brief_title>
	<detailed_description>The study do test safety effectiveness investigational drug 20089 TA use combination Lucentis treatment CNVM . In CNVM , tiny abnormal blood vessel grow retinal layer eye . These vessel fragile leak bleed . The severity symptoms depend size CNVM proximity macula ( center visual field ) . Symptoms may mild blurry distort area vision , severe , like central blind spot . Although Lucentis approve U.S. Food Drug Administration ( FDA ) treatment CNVM , study drug 20089 TA yet approve , therefore consider investigational drug . Triamcinolone Acetonide ( TA ) corticosteroid ( anti-inflammatory drug ) use treat many eye disease , : macular edema ( inflammation cause thicken macula ) , diabetic eye disease , age-related macular degeneration . TA also show effective treat neovascular AMD ( also know `` wet AMD '' ) abnormal growth blood vessel macula . Study drug 20089 experimental form corticosteroid , Triamcinolone Acetonide ( TA ) . 20089 new slow-release formula ( longer last ) intravitreal ( eye ) delivery TA . This drug release active agent TA period approximately 6 month thereby allow improvement inflammation and/or complication follow neovascular AMD . Although intravitreal Lucentis show prevent loss vision neovascular AMD patient help gain visual acuity ( well see ) , result assure monthly injection give . Since monthly injection burden patient caregiver , attempt make reduce burden combine available treatment option . We hope combine 20089 TA Lucentis decrease retinal inflammation , closure leaky vessel decrease number monthly injection could achieve .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>1 . Male Female subject , 55 year age old . 2 . Diagnosis active , subfoveal choroidal neovascular membrane ( CNVM ) due age relate macular degeneration ( AMD ) 3 . Visual acuity 20/25 20/400 study eye . 1 . Subjects receive corticosteroid via route past 30 day . 2 . In opinion investigator , patient know steroidresponder . 3 . Subjects history uncontrolled glaucoma ( Primary Secondary ) 4 . History ocular surgery ( invasive noninvasive ) past 90 day 5 . Intravitreal treatment antiVEGF agent e.g . bevacizumab , ranibizumab , pegaptanib within 30 day enrollment ( Day 0 ) examination . 6 . Patients require systemic steroid ( great 15 mg daily mouth ) systemic immunomodulatory agent . 7 . Active ocular periocular infection ( i.e. , bacterial , viral , parasitic fungal ) either eye history herpetic ocular infection either eye . 8 . Media opacity study eye preclude observation photography fundus . 9 . Any clinically significant medical psychological condition , opinion Investigator , would jeopardize safety patient affect validity study result . 10 . Participation clinical trial investigational drug device within 30 day screen visit . 11 . Known history allergy corticosteroid . 12 . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Choroidal neovascular membrane</keyword>
	<keyword>CNV</keyword>
	<keyword>AMD</keyword>
	<keyword>Age-relate Macular Degeneration</keyword>
	<keyword>CNVM</keyword>
	<keyword>subfoveal</keyword>
</DOC>